Check Out Minerva Surgical Inc. (UTRS)’s Trade Data Rather Than the Analysts’ Views

Minerva Surgical Inc. (NASDAQ: UTRS) stock jumped 6.19% on Monday to $0.22 against a previous-day closing price of $0.21. With 0.29 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.81 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $0.2395 whereas the lowest price it dropped to was $0.2100. The 52-week range on UTRS shows that it touched its highest point at $6.04 and its lowest point at $0.15 during that stretch. It currently has a 1-year price target of $5.00.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of UTRS was down-trending over the past week, with a drop of -9.57%, but this was up by 25.28% over a month. Three-month performance dropped to -41.33% while six-month performance fell -91.04%. The stock lost -95.83% in the past year, while it has lost -0.18% so far this year. A look at the trailing 12-month EPS for UTRS yields -0.61 with Next year EPS estimates of -1.38. For the next quarter, that number is -0.28. This implies an EPS growth rate of -16.50% for this year and -9.50% for next year.

Float and Shares Shorts:

At present, 28.61 million UTRS shares are outstanding with a float of 26.84 million shares on hand for trading. On Dec 29, 2022, short shares totaled 0.92 million, which was 3.12% higher than short shares on Nov 29, 2022. In addition to Mr. Joel R. Jung MBA as the firm’s Chief Financial Officer, Mr. Dominique J. Filloux serves as its Chief Operating Officer.

Institutional Ownership:

Through their ownership of 71.42% of UTRS’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 13.60% of UTRS, in contrast to 11.30% held by mutual funds. Shares owned by individuals account for 1.00%. As the largest shareholder in UTRS with 4.79% of the stake, AWM Investment Co., Inc. holds 1,388,515 shares worth 1,388,515. A second-largest stockholder of UTRS, Luminus Management LLC, holds 998,663 shares, controlling over 3.45% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in UTRS, holding 415,160 shares or 1.43% stake. With a 0.70% stake in UTRS, the Bridgeway Ultra Small Company Mar is the largest stakeholder. A total of 202,200 shares are owned by the mutual fund manager. The iShares Tr. – Micro Cap ETF, which owns about 0.11% of UTRS stock, is the second-largest Mutual Fund holder. It holds 31,392 shares valued at 7000.0. Vanguard Extended Market Index Fu holds 0.07% of the stake in UTRS, owning 19,180 shares worth 4277.0.


An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Sep 29, 2022, UTRS reported revenue of $12.97M and operating income of -$4.90M. The EBITDA in the recently reported quarter was -$2.22M and diluted EPS was -$0.20.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for UTRS since 1 analysts follow the stock currently. There are 0 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With UTRS analysts setting a high price target of $5.00 and a low target of $5.00, the average target price over the next 12 months is $5.00. Based on these targets, UTRS could surge 2172.73% to reach the target high and rise by 2172.73% to reach the target low. Reaching the average price target will result in a growth of 2172.73% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. UTRS will report FY 2022 earnings on 03/06/2024. Analysts have provided yearly estimates in a range of -$1.26 being high and -$1.26 being low. For UTRS, this leads to a yearly average estimate of -$1.26. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Minerva Surgical Inc. surprised analysts by -$0.12 when it reported -$0.40 EPS against a consensus estimate of -$0.28. The surprise factor in the prior quarter was $0.14. Based on analyst estimates, the high estimate for the next quarter is -$0.28 and the low estimate is -$0.28. The average estimate for the next quarter is thus -$0.28.

Summary of Insider Activity:

Insiders traded UTRS stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 735,799 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *